Business Context and Reporting Period
Company: ProMIS Neurosciences Inc. (PMN)
Reporting Period: Quarter ended September 30, 2024 (Q3 2024)
Business Overview: ProMIS is a clinical-stage biopharmaceutical company developing antibody therapies for neurodegenerative diseases, specifically Alzheimer's disease (AD), multiple system atrophy (MSA), and amyotrophic lateral sclerosis (ALS). The company utilizes a proprietary technology platform to target toxic, misfolded proteins. Key product candidates include PMN310 (AD), PMN267 (ALS), and PMN442 (MSA). The company has no product revenue and relies on financing to fund operations.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $4.43M | $2.52M | $10.83M | $10.39M |
| Net Income (Loss) | $9.28M | $(2.36M) | $3.02M | $(9.63M) |
| EPS (Basic & Diluted) | $0.31 | $(0.19) | $0.13 | $(0.98) |
| Cash and Equivalents (End of Period) | $21.54M (as of Sept 30, 2024) | |||
| Warrant Liability | $14.26M (as of Sept 30, 2024) | |||
| Accumulated Deficit | $(90.45M) (as of Sept 30, 2024) |
Note: Net income for Q3 and YTD 2024 is primarily driven by a non-cash gain of $16.97M and $17.01M, respectively, from the change in fair value of financial instruments (warrant liabilities), offset by a $3.49M loss on the issuance of shares in the July 2024 PIPE.
Material Changes vs. Prior Period
- Financing Activity: In July 2024, the company completed a Private Investment in Public Equity (PIPE) raising approximately $30.3 million in gross proceeds. This transaction triggered the mandatory conversion of all outstanding Series 2 Convertible Preferred Shares into common shares.
- Operating Expenses: Research and Development (R&D) expenses increased significantly to $2.56M in Q3 2024 from $1.14M in Q3 2023, driven by the advancement of the PMN310 Phase 1a clinical trial. General and Administrative (G&A) expenses also rose to $1.87M from $1.38M, partly due to a one-time CEO bonus.
- Warrant Liability: The warrant liability increased from $94,185 at year-end 2023 to $14.26M at September 30, 2024, due to the issuance of new warrants in the July 2024 PIPE. The subsequent decrease in fair value of these warrants generated the significant non-cash gain reported in the income statement.
- Liquidity: Cash balances increased from $12.60M at December 31, 2023, to $21.54M at September 30, 2024, primarily due to the July 2024 financing.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. Despite the recent financing, the company expects to continue incurring net losses and will require additional funding to support clinical trials and operations.
- Clinical Outlook:
- PMN310 (AD): Phase 1a SAD study enrollment completed in May 2024. Topline data released in July 2024 showed linear dose proportionality and blood-brain barrier penetration. A Phase 1b proof-of-concept trial in AD patients is expected to initiate in Q4 2024.
- PMN267 (ALS) & PMN442 (MSA): Both candidates are humanized and ready for IND-enabling studies, subject to resource availability.
- Internal Controls: The company identified a material weakness in internal control over financial reporting related to insufficient review controls over fair value calculations of financial instruments (specifically the July 2024 PIPE warrant liability). Remediation efforts are underway.
- Risk Factors: Key risks include the inability to raise additional capital, the uncertainty of clinical trial outcomes, and the potential for significant dilution from warrant exercises.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash sufficiency given the "substantial doubt" disclosure and the high burn rate associated with clinical trials.
- Warrant Liability Volatility: Monitor the fair value of the $14.26M warrant liability, as fluctuations will significantly impact reported net income/loss without affecting cash flow.
- Internal Control Remediation: Track the progress of remediation for the identified material weakness in financial reporting controls.
- PMN310 Phase 1b Initiation: Confirm the start date and enrollment progress of the Phase 1b trial in AD patients expected in Q4 2024.
- Shareholder Approval: Note that shareholder approval for Tranche A and B warrants was obtained in October 2024, enabling potential future dilution upon milestone achievement.